Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SPN-821 as an Adjunctive Therapy in Adults With Major Depressive Disorder
Conditions
Interventions
SPN-821 2400 mg
Placebo
Locations
1
United States
Collaborative Neuroscience Network
Garden Grove, California, United States
Start Date
January 19, 2026
Primary Completion Date
December 31, 2026
Completion Date
January 31, 2027
Last Updated
March 24, 2026
NCT06793397
NCT07025720
NCT07462013
NCT06804525
NCT07388004
NCT07228468
Lead Sponsor
Supernus Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions